Prairiewood Capital LLC Takes Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Prairiewood Capital LLC purchased a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 20,800 shares of the biotechnology company’s stock, valued at approximately $223,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AVXL. Geode Capital Management LLC lifted its stake in Anavex Life Sciences by 2.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after purchasing an additional 51,946 shares in the last quarter. Nwam LLC purchased a new position in Anavex Life Sciences during the third quarter worth approximately $5,172,000. Charles Schwab Investment Management Inc. boosted its stake in Anavex Life Sciences by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock worth $3,783,000 after buying an additional 14,892 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Anavex Life Sciences by 483.8% in the 2nd quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after buying an additional 386,537 shares in the last quarter. Finally, Barclays PLC increased its stake in shares of Anavex Life Sciences by 70.4% in the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock worth $882,000 after acquiring an additional 64,101 shares during the last quarter. 31.55% of the stock is currently owned by institutional investors and hedge funds.

Anavex Life Sciences Stock Down 9.3 %

Shares of Anavex Life Sciences stock opened at $9.21 on Tuesday. The firm has a market cap of $781.19 million, a PE ratio of -17.71 and a beta of 0.70. Anavex Life Sciences Corp. has a 52 week low of $3.25 and a 52 week high of $14.44. The business’s fifty day simple moving average is $9.73 and its 200-day simple moving average is $7.27.

Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. As a group, equities analysts expect that Anavex Life Sciences Corp. will post -0.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on AVXL. HC Wainwright boosted their price target on shares of Anavex Life Sciences from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, December 26th. D. Boral Capital reissued a “buy” rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research note on Monday, January 13th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.